Tecentriq, Avastin Regimen Beats Anti-PD-L1 Monotherapy in MMR-Deficient, MSI-High Colorectal Cancer
Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...
Jazz Pharma to Submit Ziihera Data in First-Line HER2-Positive Gastroesophageal Cancer to Regulators
In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.
Jazz Pharmaceuticals (NASDAQ:JAZZ) used an investor call following the ASCO Gastrointestinal Cancer Symposium to highlight ...
Zacks Investment Research on MSN
Merck in talks to buy Revolution Medicines per Financial Times report
A recent Financial Times report stated that Merck MRK is in talks to buy Redwood City, CA-based cancer biotech, Revolution ...
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major’s shares have gained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback